Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Elnakady, Yasser A
Wiedmann, Romina M
Vollmar, Angelika M
MetadataShow full item record
AbstractPretubulysin is a natural product that is found in strains of myxobacteria in only minute amounts. It represents the first enzyme-free intermediate in the biosynthesis of tubulysins and undergoes post-assembly acylation and oxidation reactions. Pretubulysin inhibits the growth of cultured mammalian cells, as do tubulysins, which are already in advanced preclinical development as anticancer and antiangiogenic agents. The mechanism of action of this highly potent compound class involves the depolymerization of microtubules, thereby inducing mitotic arrest. Supply issues with naturally occurring derivatives can now be circumvented by the total synthesis of pretubulysin, which, in contrast to tubulysin, is synthetically accessible in gram-scale quantities. We show that the simplified precursor is nearly equally potent to the parent compound. Pretubulysin induces apoptosis and inhibits cancer cell migration and tubulin assembly in vitro. Consequently, pretubulysin appears to be an ideal candidate for future development in preclinical trials and is a very promising early lead structure in cancer therapy.
CitationPretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy. 2012, 7 (5):e37416 PLoS ONE
AffiliationHelmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Department of Pharmaceutical Biotechnology, Saarland University, Saarbrücken, Germany.
The following license files are associated with this item:
- Anti-angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives.
- Authors: Rath S, Liebl J, Fürst R, Ullrich A, Burkhart JL, Kazmaier U, Herrmann J, Müller R, Günther M, Schreiner L, Wagner E, Vollmar AM, Zahler S
- Issue date: 2012 Nov
- Simplified pretubulysin derivatives and their biological effects on cancer cells.
- Authors: Kubisch R, von Gamm M, Braig S, Ullrich A, Burkhart JL, Colling L, Hermann J, Scherer O, Müller R, Werz O, Kazmaier U, Vollmar AM
- Issue date: 2014 Mar 28
- Pretubulysin, a potent and chemically accessible tubulysin precursor from Angiococcus disciformis.
- Authors: Ullrich A, Chai Y, Pistorius D, Elnakady YA, Herrmann JE, Weissman KJ, Kazmaier U, Müller R
- Issue date: 2009
- Pretubulysin: a new option for the treatment of metastatic cancer.
- Authors: Braig S, Wiedmann RM, Liebl J, Singer M, Kubisch R, Schreiner L, Abhari BA, Wagner E, Kazmaier U, Fulda S, Vollmar AM
- Issue date: 2014 Jan 16
- 3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells.
- Authors: Jiang JD, Davis AS, Middleton K, Ling YH, Perez-Soler R, Holland JF, Bekesi JG
- Issue date: 1998 Dec 1